AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29577798 — intervention group
Group type: EXPERIMENTAL
Intervention: Art Intervention Program (12 sessions, once a week)
Number of subjects: 17
Study 27327502 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 201
Study 27327502 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 201
Study 24897743 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT group) - six sessions of a standardized hospital-based physical therapy program
Number of subjects: 61
Study 24897743 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (no-PT group)
Number of subjects: 61
Study 24897743 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT group)
Number of subjects: 61
Study 21767018 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-test promotion messages
Number of subjects: 1052
Study 21767018 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 1052
Study 21767018 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 1052
Study 21767018 — intervention group
Group type: COMPARATOR
Intervention: No message control
Number of subjects: 1052
Study 20722677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (37.5 mg)/Acetaminophen (325 mg)
Number of subjects: 163
Study 20722677 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (300 mg)
Number of subjects: 163
Study 20722677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen
Number of subjects: 163
Study 20722677 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 163
Study 19041063 — intervention group
Group type: EXPERIMENTAL
Intervention: ATO 0.15 mg/kg i.v. x 7 days + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Number of subjects: 48
Study 19041063 — intervention group
Group type: EXPERIMENTAL
Intervention: ATO 0.25 mg/kg i.v. x 7 days + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Number of subjects: 48
Study 19041063 — intervention group
Group type: COMPARATOR
Intervention: No ATO + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Number of subjects: 48
Study 19041063 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (ATO + AA + melphalan)
Number of subjects: 48
Study 17081400 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Number of subjects: 213
Study 17081400 — intervention group
Group type: COMPARATOR
Intervention: Cassin placebo
Number of subjects: 213
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: E/A ratio at tips of mitral valve leaflets
Number of subjects: 40
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial filling fraction
Number of subjects: 40
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolumic relaxation time
Number of subjects: 40
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: E-wave deceleration time
Number of subjects: 40
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: E-wave propagation rate
Number of subjects: 40
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: E'/A' ratio of diastolic excursion of lateral mitral annulus
Number of subjects: 40
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler parameters of LV diastolic function
Number of subjects: 40
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: E/A at tips of mitral valve
Number of subjects: 40
Study 14608283 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue-derived E'/A'
Number of subjects: 40
Study 10644315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium 40 microg
Number of subjects: 72
Study 10644315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 10644315 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 72
Study 8824689 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg nefazodone once daily in the morning (treatment 1)
Number of subjects: 24
Study 8824689 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg nefazodone once daily in the evening (treatment 2)
Number of subjects: 24
Study 8824689 — intervention group
Group type: COMPARATOR
Intervention: 200 mg nefazodone twice daily (treatment 3)
Number of subjects: 24
Study 1454350 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation laser panretinal photocoagulation (MORE)
Number of subjects: 35
Study 1454350 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (NOMORE)
Number of subjects: 35
Study 1454350 — intervention group
Group type: EXPERIMENTAL
Intervention: All study patients
Number of subjects: 35
Study 3966664 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with bupivacaine 0.25 mg X kg‐1
Number of subjects: 32
Study 3966664 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane/oxygen anesthesia
Number of subjects: 32
Study 3966664 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25 mg X kg‐1 im without surgery (volunteers)
Number of subjects: 32
Study 31679187 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar anatomy parameters measured via CT scanning
Number of subjects: 476
Study 29679660 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (N=75)
Number of subjects: 304
Study 29679660 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (N=78)
Number of subjects: 304
Study 29679660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (N=75)
Number of subjects: 304
Study 29679660 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control (N=76)
Number of subjects: 304
Study 26785715 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid alone (n=168)
Number of subjects: 341
Study 26785715 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid plus risk assessment (n=173)
Number of subjects: 341
Study 24662322 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CGRP monoclonal antibody (up to 2000 mg)
Number of subjects: 31
Study 24662322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 22168128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 30
Study 22168128 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia
Number of subjects: 30
Study 22168128 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 20712261 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.50%
Number of subjects: 120
Study 20712261 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic bupivacaine 0.50%
Number of subjects: 120
Study 20712261 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine-hyaluronidase 10 IU x ml(‐1)
Number of subjects: 120
Study 20712261 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic bupivacaine-hyaluronidase 10 IU x ml(‐1)
Number of subjects: 120
Study 20712261 — intervention group
Group type: COMPARATOR
Intervention: Control group (hyaluronidase)
Number of subjects: 120
Study 20712261 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 120
Study 17510208 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 + CPT‐11
Number of subjects: 400
Study 16637748 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive face flanked by negative faces
Number of subjects: 0
Study 16637748 — intervention group
Group type: COMPARATOR
Intervention: Negative face flanked by positive faces
Number of subjects: 0
Study 16637748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonemotional stimuli
Number of subjects: 0
Study 14582817 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg
Number of subjects: 0
Study 14582817 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine, 50 mg
Number of subjects: 0
Study 14582817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10975012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (total 15 mg/kg, 2 doses)
Number of subjects: 135
Study 10975012 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid (NA: 55 mg/kg daily for 5 days)
Number of subjects: 135
Study 10975012 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid (NA)
Number of subjects: 135
Study 10975012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 135
Study 8630595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 38
Study 8630595 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 38
Study 1574933 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cold therapy
Number of subjects: 0
Study 1574933 — intervention group
Group type: COMPARATOR
Intervention: Hot mud-pack therapy
Number of subjects: 0
Study 3882071 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of contrast material (60 to 350 mL)
Number of subjects: 193
Study 3882071 — intervention group
Group type: COMPARATOR
Intervention: No infusion of contrast material
Number of subjects: 193
Study 3882071 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of contrast material in high-risk group
Number of subjects: 193
Study 3882071 — intervention group
Group type: COMPARATOR
Intervention: No infusion of contrast material in high-risk group
Number of subjects: 193
Study 30353444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg + Morphine
Number of subjects: 1862
Study 30353444 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 180 mg
Number of subjects: 1862
Study 28183002 — intervention group
Group type: EXPERIMENTAL
Intervention: UCBfree
Number of subjects: 72
Study 28183002 — intervention group
Group type: EXPERIMENTAL
Intervention: UCBfree/TSB ratio
Number of subjects: 72
Study 28183002 — intervention group
Group type: COMPARATOR
Intervention: TSB-based phototherapy treatment
Number of subjects: 72
Study 25500982 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional arm of the EAGLE study
Number of subjects: 34
Study 23320487 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone LAI
Number of subjects: 50
Study 23320487 — intervention group
Group type: COMPARATOR
Intervention: oral atypical antipsychotic medication
Number of subjects: 50
Study 21574750 — intervention group
Group type: EXPERIMENTAL
Intervention: Value and relatedness cues in predicting likelihood of remembering items (JOLs)
Number of subjects: 0
Study 21574750 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of study time for each item based on value and relatedness
Number of subjects: 0
Study 18293602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic ball attachments (ruby)
Number of subjects: 40
Study 18293602 — intervention group
Group type: COMPARATOR
Intervention: Titanium ball attachments
Number of subjects: 40
Study 16531596 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-minute booster seat training
Number of subjects: 225
Study 16531596 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-minute booster seat training and free booster seat with installation
Number of subjects: 225
Study 16531596 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 225
Study 15545855 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 doses of Pn‐PD at 2, 4, 6 and 12‐15 months
Number of subjects: 154
Study 15545855 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of Pn‐PD at 2, 4 and 6 months and 1 dose of 23‐valent polysaccharide vaccine (PncPS) at 12‐15 months
Number of subjects: 154
Study 15545855 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of hepatitis B vaccine at 2, 4 and 6 months and Pn‐PD at 12‐15 months
Number of subjects: 154
Study 10770194 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone administration in normal men; n = 8
Number of subjects: 24
Study 10770194 — intervention group
Group type: COMPARATOR
Intervention: Placebo in normal men; n = 8
Number of subjects: 24
Study 10770194 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement therapy in patients with chronic hypocortisolism; n = 8
Number of subjects: 24
Study 10770194 — intervention group
Group type: EXPERIMENTAL
Intervention: After withdrawal of prednisone in patients with chronic hypocortisolism; n = 8
Number of subjects: 24
Study 9327779 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg QD for 12 weeks increasing to 20 mg QD for 12 weeks
Number of subjects: 84
Study 9327779 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 100 mg TID for 24 weeks
Number of subjects: 84
Study 1588979 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxamine (10 mg)
Number of subjects: 19
Study 1588979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3904456 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amnioinfusion
Number of subjects: 0
Study 3904456 — intervention group
Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 0
Study 31904715 — intervention group
Group type: EXPERIMENTAL
Intervention: VL5 (5% velocity loss)
Number of subjects: 28
Study 31904715 — intervention group
Group type: COMPARATOR
Intervention: VL20 (20% velocity loss)
Number of subjects: 28
Study 29341843 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 338
Study 29341843 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 338
Study 29341843 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 338
Study 26888908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (1.0 g once daily)
Number of subjects: 565
Study 26888908 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (4.5 g every 8 h)
Number of subjects: 565
Study 23846567 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker tool
Number of subjects: 198
Study 23846567 — intervention group
Group type: COMPARATOR
Intervention: WHO clinical staging
Number of subjects: 198
Study 22770792 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mL 1% lidocaine paracervical block
Number of subjects: 50
Study 22770792 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 50
Study 20031291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided measurement of tumor thickness
Number of subjects: 13
Study 20031291 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection method
Number of subjects: 13
Study 20031291 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique using elastic needles with a metal core
Number of subjects: 13
Study 17110397 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-hMG (MENOPUR)
Number of subjects: 731
Study 17110397 — intervention group
Group type: COMPARATOR
Intervention: rFSH (GONAL-F)
Number of subjects: 731
Study 16219143 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 294
Study 16219143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (TCM plus NP regimen)
Number of subjects: 294
Study 16219143 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 294
Study 12168125 — intervention group
Group type: EXPERIMENTAL
Intervention: Paratrend 7 system (continuous blood gas monitoring)
Number of subjects: 10
Study 12168125 — intervention group
Group type: COMPARATOR
Intervention: Standard system of blood gas analysis (intermittent sampling)
Number of subjects: 10
Study 10640121 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in patient-centred consulting (GPs 0.5 days; nurses 1.5 days; two optional follow-up half-days)
Number of subjects: 49
Study 10640121 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in patient-centred consulting
Number of subjects: 49
Study 7832387 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (RHE) at a loading dose of 300 U/kg iv 3 times/week for 1 week followed by 150 U/kg 3 times/week (N = 13) or 100 U/kg 3 times/week (N = 7)
Number of subjects: 40
Study 7832387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RHE)
Number of subjects: 40
Study 1977080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose zidovudine (300 mg daily)
Number of subjects: 67
Study 1977080 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose zidovudine (600 mg daily)
Number of subjects: 67
Study 1977080 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose zidovudine (1500 mg daily)
Number of subjects: 67
Study 1977080 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (4.8 g) with zidovudine
Number of subjects: 67
Study 1977080 — intervention group
Group type: COMPARATOR
Intervention: All doses of zidovudine (300 mg, 600 mg, 1500 mg)
Number of subjects: 67
Study 344850 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 125 mg
Number of subjects: 16
Study 344850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine SO4 30 mg
Number of subjects: 16
Study 344850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30870235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ)
Number of subjects: 135
Study 30870235 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (DTBZ)
Number of subjects: 135
Study 30870235 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (VBZ)
Number of subjects: 135
Study 28872918 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (E-E)
Number of subjects: 0
Study 28872918 — intervention group
Group type: COMPARATOR
Intervention: Edaravone (P-E)
Number of subjects: 0
Study 26686385 — intervention group
Group type: EXPERIMENTAL
Intervention: hIL1bQb vaccine (900 µg, six injections)
Number of subjects: 48
Study 26686385 — intervention group
Group type: EXPERIMENTAL
Intervention: hIL1bQb vaccine
Number of subjects: 48
Study 26686385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24971700 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (n=12)
Number of subjects: 25
Study 24971700 — intervention group
Group type: COMPARATOR
Intervention: Passive sitting (Control)
Number of subjects: 25
Study 23039299 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (10 mmol bolus, 5 mmol/h infusion for 6 hours)
Number of subjects: 39
Study 23039299 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 39
Study 19240614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural nerve harvesting (Group 1: n = 10, Group 2: n = 6, Group 3: n = 8)
Number of subjects: 24
Study 19240614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural nerve harvesting (Group 1: n = 10)
Number of subjects: 24
Study 19240614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural nerve harvesting (Group 3: n = 8)
Number of subjects: 24
Study 19240614 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 4: n = 24)
Number of subjects: 24
Study 17325559 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (AG) 24 g/d for 10 days
Number of subjects: 107
Study 17325559 — intervention group
Group type: COMPARATOR
Intervention: Glycine (G) 25 g/d for 10 days (control)
Number of subjects: 107
Study 16562417 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual TLFB administration
Number of subjects: 104
Study 16562417 — intervention group
Group type: COMPARATOR
Intervention: Group TLFB administration
Number of subjects: 104
Study 12196420 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified t10c12 CLA (3.4 g/day)
Number of subjects: 60
Study 12196420 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA mixture (3.4 g/day)
Number of subjects: 60
Study 12196420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9459332 — intervention group
Group type: EXPERIMENTAL
Intervention: Free T4 (fT4) levels
Number of subjects: 472
Study 7572573 — intervention group
Group type: EXPERIMENTAL
Intervention: Various predictors including QRS duration, coronary artery bypass grafting, basal heart rate, diastolic blood pressure, diabetes mellitus, ejection fraction, ease of suppression
Number of subjects: 0
Study 7572573 — intervention group
Group type: EXPERIMENTAL
Intervention: Various predictors including thrombolysis, coronary artery bypass grafting, diuretic use, heart rate, calcium channel blocker use, QRS duration
Number of subjects: 0
Study 2692821 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05% cream, augmented formulation (AF), once-daily application
Number of subjects: 244
Study 2692821 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide 0.05% cream, twice-daily application
Number of subjects: 244
Study 57451 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxycholecalciferol (1alpha‐H.C.C.) 1 mug daily for eleven weeks
Number of subjects: 24
Study 57451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31859682 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tracking
Number of subjects: 0
Study 31859682 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and goal setting (moderate level)
Number of subjects: 0
Study 31859682 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically meaningful use (combination of learning, goal setting, and self-tracking)
Number of subjects: 0
Study 31859682 — intervention group
Group type: COMPARATOR
Intervention: Generic app use (intensity and duration)
Number of subjects: 0
Study 27974302 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI erosion scores at Weeks 12 and 24
Number of subjects: 1022
Study 27974302 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI osteitis scores at Weeks 12 and 24
Number of subjects: 1022
Study 27974302 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI changes in synovitis at Weeks 12 and 24
Number of subjects: 1022
Study 25375780 — intervention group
Group type: EXPERIMENTAL
Intervention: EX/RP
Number of subjects: 100
Study 25375780 — intervention group
Group type: COMPARATOR
Intervention: risperidone
Number of subjects: 100
Study 25375780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EX/RP and risperidone
Number of subjects: 100
Study 23874586 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation in 10 fractions of 3 Gy, 5 fractions a week for 2 consecutive weeks with oral capecitabine 700 mg/m² twice daily throughout radiation therapy
Number of subjects: 29